Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Ptc Therapeutics (PTCT) Net Income towards Common Stockholders (2016 - 2025)

Ptc Therapeutics has reported Net Income towards Common Stockholders over the past 14 years, most recently at -$1.4 billion for Q4 2025.

  • Quarterly results put Net Income towards Common Stockholders at -$1.4 billion for Q4 2025, down 1984.71% from a year ago — trailing twelve months through Dec 2025 was -$555.9 million (down 53.02% YoY), and the annual figure for FY2025 was -$555.9 million, down 53.02%.
  • Net Income towards Common Stockholders for Q4 2025 was -$1.4 billion at Ptc Therapeutics, down from $15.9 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for PTCT hit a ceiling of $866.6 million in Q1 2025 and a floor of -$1.4 billion in Q4 2025.
  • Median Net Income towards Common Stockholders over the past 5 years was -$127.7 million (2021), compared with a mean of -$131.4 million.
  • Peak annual rise in Net Income towards Common Stockholders hit 1046.28% in 2025, while the deepest fall reached 1984.71% in 2025.
  • Ptc Therapeutics' Net Income towards Common Stockholders stood at -$143.3 million in 2021, then fell by 19.28% to -$170.9 million in 2022, then grew by 8.83% to -$155.8 million in 2023, then skyrocketed by 57.71% to -$65.9 million in 2024, then plummeted by 1984.71% to -$1.4 billion in 2025.
  • The last three reported values for Net Income towards Common Stockholders were -$1.4 billion (Q4 2025), $15.9 million (Q3 2025), and -$64.8 million (Q2 2025) per Business Quant data.